Leukemia (ALL): Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone,
and Blinatumomab in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic
What are the good and/or bad effects of adding the drug blinatumomab to different
doses of standard combinations of chemotherapy drugs?
Can standard therapy drugs can be given at lower doses (when given with blinatumomab)
in order to reduce overall side effects and be effective in treating ALL?
Basic Study Information
Purpose:Location: Cancer Center
This study will have 2 groups: subjects who do not have the Philadelphia chromosome
mutation (Ph-) and subjects who do have the mutation (Ph+). Treatments for the two
groups will be different and are outlined below.
In general, there are 3 main steps to all of the treatments. Induction/Re-Induction
treatment is given first. It is a treatment given over a short period of time (usually
only a few months) to get rid of as many of the leukemia cells as possible very quickly.
Post-Remission treatment is given next. It is given to get rid of any leukemia cells
that are left once your leukemia goes into remission and to make sure the leukemia
cells don’t come back over a short period of time (usually only a few months). Maintenance
treatment is given last. It is a lower dose treatment given over a long period of
time (up to several years) to help keep the leukemia cells from coming back.
Depending on which arm of the study you are on, Blinatumomab will be given as part
of induction/re-induction or post-remission along with standard chemotherapy.
Study Web URL: https://clinicaltrials.gov/ct2/show/NCT02143414?term=S1318&rank=1
Study Reference #: CLEU-15006
Lead Researcher (Principal Investigator)
Lead Researcher: Kristen O'Dwyer
Study Contact InformationStudy Coordinator: Haley Misch
Phone: (585) 276-4415
Additional Study Details
Learn More About These Conditions
More information about Acute lymphoblastic leukemia [ALL]
Trial Not Found
The study you are looking for is not active at this time.
Return to Search